Go Pro
→ Should You Convert a Traditional IRA to a Roth After 60? (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.12
-2.6%		$1.58
$1.00
▼
$14.64
$4.10M1.821.24 million shs75,647 shs
Prenetics Global Limited stock logo
PRE
Prenetics Global
$22.76
-0.9%		$21.78
$11.36
▼
$27.24
$387.60M0.31187,480 shs74,347 shs
10 Best Stocks to Own: Fall 2026 Cover
10 Best Stocks to Own: Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
0.00%+7.48%-25.32%-61.92%-91.80%
Prenetics Global Limited stock logo
PRE
Prenetics Global
0.00%-5.04%-10.83%+23.63%+82.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.12
-2.6%		$1.58
$1.00
▼
$14.64
$4.10M1.821.24 million shs75,647 shs
Prenetics Global Limited stock logo
PRE
Prenetics Global
$22.76
-0.9%		$21.78
$11.36
▼
$27.24
$387.60M0.31187,480 shs74,347 shs
10 Best Stocks to Own: Fall 2026 Cover
10 Best Stocks to Own: Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
0.00%+7.48%-25.32%-61.92%-91.80%
Prenetics Global Limited stock logo
PRE
Prenetics Global
0.00%-5.04%-10.83%+23.63%+82.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.001,060.71% Upside
Prenetics Global Limited stock logo
PRE
Prenetics Global
2.71
Moderate Buy$35.6756.71% Upside

Current Analyst Ratings Breakdown

Latest PRE and CVKD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Prenetics Global Limited stock logo
PRE
Prenetics Global
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$40.00
8/27/2026
Prenetics Global Limited stock logo
PRE
Prenetics Global
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$37.00
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Prenetics Global Limited stock logo
PRE
Prenetics Global
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
Prenetics Global Limited stock logo
PRE
Prenetics Global
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$30.00 ➝ $40.00
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Prenetics Global Limited stock logo
PRE
Prenetics Global
$92.39M4.16N/AN/A$9.27 per share2.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$4.90N/AN/AN/AN/A-406.41%-273.80%11/9/2026 (Estimated)
Prenetics Global Limited stock logo
PRE
Prenetics Global
-$37.71M-$4.16N/AN/AN/A-47.43%-21.41%-15.56%11/9/2026 (Estimated)

Latest PRE and CVKD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
Prenetics Global Limited stock logo
PRE
Prenetics Global
-$0.84-$0.53+$0.31-$0.52$49.85 million$46.49 million
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Prenetics Global Limited stock logo
PRE
Prenetics Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
3.73
3.73
Prenetics Global Limited stock logo
PRE
Prenetics Global
N/A
4.04
3.66

Institutional Ownership

CompanyInstitutional Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Prenetics Global Limited stock logo
PRE
Prenetics Global
25.01%

Insider Ownership

CompanyInsider Ownership
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
Prenetics Global Limited stock logo
PRE
Prenetics Global
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
53.57 million3.05 millionNot Optionable
Prenetics Global Limited stock logo
PRE
Prenetics Global
9816.87 millionN/ANot Optionable

Recent News About These Companies

Comparing Prenetics Global (NASDAQ:PRE) & Lifevantage (NASDAQ:LFVN)
September 27 at 8:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055585
Prenetics Global Limited (NASDAQ:PRE) Stock Now Rated "Moderate Buy" by Wall Street Analysts
September 25 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048319
Prenetics Global Limited (NASDAQ:PRE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 25 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-prenetics-global-limited-nasdaq-pre-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-09-25/
Prenetics Global (NASDAQ:PRE) Coverage Initiated at Craig Hallum
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031947
Craig-Hallum initiates coverage of Prenetics Global with buy
September 18, 2026  |  msn.comhttps://www.msn.com/en-us/general/general/craig-hallum-initiates-coverage-of-prenetics-global-with-buy/ar-AA2ct81W
Craig-Hallum Initiates Prenetics Global With Buy Rating, $40 Price Target
September 17, 2026  |  marketscreener.comM
Prenetics Global (NASDAQ:PRE) Earns Buy Rating from Analysts at Craig Hallum
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-prenetics-global-nasdaq-pre-earns-buy-rating-from-analysts-at-craig-hallum-2026-09-17/
Prenetics Global Limited (NASDAQ:PRE) Receives Consensus Rating of "Moderate Buy" from Brokerages
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-prenetics-global-limited-nasdaq-pre-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-08-31/
Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
August 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prenetics-im8-ceo-and-cfo-purchase-1-0-million-of-shares-in-the-open-market-following-second-quarter-results-1036493829
Insider Buying: Prenetics Global (NASDAQ:PRE) CFO Purchases 5,100 Shares
August 27, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pre-insider-buying-and-selling-2026-08-27/
Prenetics Global CEO and CFO purchase $1M of shares in open market
August 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/prenetics-global-ceo-and-cfo-purchase-1m-of-shares-in-open-market/ar-AA2aXCUc
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351356/0/en/prenetics-im8-ceo-and-cfo-purchase-1-0-million-of-shares-in-the-open-market-following-second-quarter-results.html
Prenetics Global (NASDAQ:PRE) CEO Danny Sheng Wu Yeung Purchases 7,500 Shares of Stock
August 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pre-insider-buying-and-selling-2026-08-25/
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
August 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4939295-prenetics-global-limited-pre-q2-2026-earnings-call-transcript
Prenetics’ IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
August 20, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prenetics-im8-announces-two-time-golden-globe-nominated-actress-and-producer-lily-collins-as-im8-global-ambassador-and-shareholder-in-multi-year-partnership-1036478664
Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prenetics-im8-brings-lily-collins-on-board-as-global-ambassador-and-shareholder-amid-raised-2026-2027-guidance?utm_source=marketbeat.com&utm_medium=referral
Prenetics’ IM8 Names Lily Collins First Film and Television Global Ambassador, Raises 2026 Revenue Guidance
August 20, 2026  |  quiverquant.comQ
Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348417/0/en/prenetics-im8-announces-two-time-golden-globe-nominated-actress-and-producer-lily-collins-as-im8-global-ambassador-and-shareholder-in-multi-year-partnership.html
Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69341438-prenetics-global-limited-prenetics-im8-reports-q2-2026-revenue-growth-of-288-yoy-raises-fy-2026-im8-revenue-guidance-to-dollar-220-230-million-399.htm
Prenetics Names Veteran Wall Street Analyst Caroline Levy to Board as Independent Director
August 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRE/pressreleases/3907494/prenetics-names-veteran-wall-street-analyst-caroline-levy-to-board-as-independent-director/
Prenetics Reports Q2 2026 Revenue Up 288%, IM8 Revenue Up 359%, and Raises Full-Year Guidance
August 18, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.12 -0.03 (-2.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 +0.01 (+1.34%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Prenetics Global stock logo

Prenetics Global NASDAQ:PRE

$22.76 -0.21 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$22.77 +0.01 (+0.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas